JP2021521230A5 - - Google Patents

Info

Publication number
JP2021521230A5
JP2021521230A5 JP2020556885A JP2020556885A JP2021521230A5 JP 2021521230 A5 JP2021521230 A5 JP 2021521230A5 JP 2020556885 A JP2020556885 A JP 2020556885A JP 2020556885 A JP2020556885 A JP 2020556885A JP 2021521230 A5 JP2021521230 A5 JP 2021521230A5
Authority
JP
Japan
Prior art keywords
peptide
insulin
chain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020556885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521230A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027484 external-priority patent/WO2019204206A1/en
Publication of JP2021521230A publication Critical patent/JP2021521230A/ja
Publication of JP2021521230A5 publication Critical patent/JP2021521230A5/ja
Pending legal-status Critical Current

Links

JP2020556885A 2018-04-16 2019-04-15 グルコース応答性インスリン Pending JP2021521230A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658372P 2018-04-16 2018-04-16
US62/658,372 2018-04-16
PCT/US2019/027484 WO2019204206A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Publications (2)

Publication Number Publication Date
JP2021521230A JP2021521230A (ja) 2021-08-26
JP2021521230A5 true JP2021521230A5 (enExample) 2022-04-25

Family

ID=68239869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556885A Pending JP2021521230A (ja) 2018-04-16 2019-04-15 グルコース応答性インスリン

Country Status (8)

Country Link
US (1) US20210214412A1 (enExample)
EP (1) EP3781147A4 (enExample)
JP (1) JP2021521230A (enExample)
KR (1) KR20210005630A (enExample)
CN (1) CN112423741A (enExample)
AU (1) AU2019255611A1 (enExample)
CA (1) CA3097359A1 (enExample)
WO (1) WO2019204206A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
EP3707145B1 (en) 2017-11-09 2023-06-21 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7640462B2 (ja) * 2019-03-29 2025-03-05 ノヴォ ノルディスク アー/エス グルコース感受性インスリン誘導体
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CA3173417A1 (en) * 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
PH12023500012A1 (en) * 2020-11-19 2024-03-11 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CN119136821A (zh) * 2022-02-17 2024-12-13 雷沃洛生物医疗有限公司 产生衍生自伴侣蛋白60.1的肽的方法
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体,その製法,及びヒト型インシュリンの製造法
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ ノルディスク アクティーゼルスカブ 新規グルコース依存性インスリン
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
WO2011103575A1 (en) * 2010-02-22 2011-08-25 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
WO2014093696A2 (en) * 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
EP3291828A4 (en) * 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins

Similar Documents

Publication Publication Date Title
EP1360202B1 (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
JP7596268B2 (ja) グルカゴン、glp-1及びgip受容体の全てに活性を有する三重活性体と、インスリンとを含む薬学組成物
JP2018515088A5 (enExample)
JP2014534265A5 (enExample)
CA2862516A1 (en) Compositions and methods of use for treating metabolic disorders
JP7536030B2 (ja) 増殖分化因子15併用療法
US10822386B2 (en) Insulin analogues with enhanced stability and reduced mitogenicity
CN105324397A (zh) 胰岛素-肠促胰岛素缀合物
JP2013501818A (ja) 修飾された血管作動性腸管ペプチド
EP2373681A1 (en) Pharmaceutical compositions
JP2017536337A5 (enExample)
JP2021533204A5 (enExample)
CN107108716A (zh) 双相性单链胰岛素类似物
EP2804621A1 (en) Glutamic acid-stabilized insulin analogues
CA3139946A1 (en) Variant single-chain insulin analogues
JP2022551233A (ja) 異なる構造のglp-1アナログペプチド修飾二量体およびその調製方法のii型糖尿病の治療における用途
CN103501801A (zh) 甲状旁腺激素类似物、其组合物和用途
JP2017500316A5 (enExample)
CN106279430B (zh) Exendin‑4类似物融合蛋白及其制备方法和用途
JP2017524675A5 (enExample)
WO2022227707A1 (zh) 一种双靶点融合蛋白的制备方法和应用
JP2010043001A (ja) Glp−1誘導体とその用途
JP2014519514A5 (enExample)
WO2015180634A1 (zh) 用于治疗2型糖尿病的长效肠激素多肽类似物及应用
Linderoth et al. GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity